Jaguar Health Inc. (NASDAQ:JAGX) had good news to share on February 7, 2023, as the Company was notified by The Nasdaq Stock Market LLC (“Nasdaq”) that it had achieved compliance with Nasdaq’s minimum bid price requirement. This marks an important milestone in Jaguar’s growth story, and is a testament to the Company’s commitment to delivering value to its shareholders.
Jaguar is thrilled to have regained compliance with Nasdaq and is now focusing on two pivotal clinical events expected to take place within the next 6 months. These events are set to be game-changers for the company, providing tremendous value and recognition. Enrollment in the OnTarget trial is scheduled to wrap up in the second quarter of 2023, while the proof-of-concept trial of crofelemer for short bowel syndrome (SBS) and congenital diarrheal disorders (CDD) with intestinal failure will also be conducted. This is an exciting time for Jaguar and its stakeholders!
About Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics & Jaguar Animal Health
Jaguar Health, Inc. is an innovative, commercial stage pharmaceuticals company dedicated to creating novel, plant-based, non-opioid solutions to treat people and animals suffering from GI distress, such as chronic diarrhea. Through its wholly owned subsidiary, Napo Pharmaceuticals, Inc., Jaguar Health is developing proprietary plant-based medicines that are sustainably sourced from rainforest areas. Currently, the company is conducting a pivotal Phase 3 clinical trial, appropriately entitled OnTarget, to evaluate the efficacy of its drug candidate, crofelemer, for the prevention of diarrhea in adult cancer patients receiving targeted therapy. Additionally, Jaguar Health has established Napo Therapeutics S.p.A. in Milan, Italy, to expand crofelemer’s reach in Europe. Jaguar Animal Health is a trade name of Jaguar Health.